HUTCHMED (NASDAQ:HCM) Stock Crosses Above 50-Day Moving Average – Here’s What Happened

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCMGet Free Report) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $14.40 and traded as high as $14.87. HUTCHMED shares last traded at $14.76, with a volume of 5,329 shares traded.

Wall Street Analyst Weigh In

Several research firms have weighed in on HCM. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a report on Monday, January 19th. Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $20.88.

Get Our Latest Analysis on HCM

HUTCHMED Stock Up 0.1%

The company has a 50-day simple moving average of $14.40 and a 200-day simple moving average of $15.21. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65.

Institutional Trading of HUTCHMED

Hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp lifted its position in shares of HUTCHMED by 1.2% during the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after purchasing an additional 3,801 shares during the last quarter. M&G PLC increased its stake in HUTCHMED by 0.4% in the 2nd quarter. M&G PLC now owns 259,617 shares of the company’s stock worth $3,894,000 after buying an additional 924 shares during the period. Amundi lifted its holdings in HUTCHMED by 41.9% during the 3rd quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after buying an additional 65,898 shares in the last quarter. Jane Street Group LLC boosted its position in HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after buying an additional 124,771 shares during the period. Finally, UBS Group AG grew its stake in HUTCHMED by 112.8% in the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares in the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

About HUTCHMED

(Get Free Report)

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.

Further Reading

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.